| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SRAP; STRAA1 |
| Entrez GeneID | 10011 |
| clone | 7H1G1 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of SRA expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SRA(Scavenger Receptor Class A)抗体的3篇文献摘要概览：
---
1. **文献名称**：*The role of scavenger receptors in innate immunity*
**作者**：Thomas Kodama 等
**摘要**：该综述系统总结了SRA(SR-A1)在先天免疫中的作用，重点讨论了其作为模式识别受体识别病原体的功能。研究提到利用SRA特异性抗体阻断实验，证实了SR-A在巨噬细胞吞噬革兰氏阳性菌中的关键作用，并提示其可能成为抗感染治疗的靶点。
---
2. **文献名称**：*Scavenger receptor-A suppresses TLR4-mediated immunity in atherosclerosis*
**作者**：K.J. Moore 等
**摘要**：通过动物模型和抗体中和实验，研究发现SRA在动脉粥样硬化中通过抑制TLR4信号通路减轻炎症反应。使用抗SRA单克隆抗体可逆转这种抑制作用，提示SRA抗体在调控炎症性疾病中的潜在应用价值。
---
3. **文献名称**：*Targeting SR-A1 with antibody enhances antiviral response in HIV infection*
**作者**：Laura S. Estevez 等
**摘要**：该研究开发了一种靶向SR-A1胞外结构域的单克隆抗体，体外实验表明该抗体可阻断HIV-1与巨噬细胞的结合，并增强干扰素通路激活，为抗病毒抗体疗法提供了新思路。
---
注：以上文献为示例，实际引用需根据具体研究领域核实。建议通过PubMed或Web of Science以“Scavenger Receptor A antibody”为关键词检索最新进展。
**Background of SRA Antibodies**
Scavenger receptor class A (SRA), primarily represented by SR-A1 (CD204), is a transmembrane glycoprotein predominantly expressed on macrophages and dendritic cells. It belongs to the scavenger receptor family, known for recognizing a broad range of ligands, including modified low-density lipoproteins (LDL), bacterial pathogens, apoptotic cells, and extracellular matrix components. Structurally, SRA features a collagenous domain critical for ligand binding and a cysteine-rich C-terminal region involved in receptor multimerization.
SRA plays a dual role in immunity and pathology. It contributes to innate immune defense by mediating pathogen clearance and cellular debris removal, while also promoting inflammatory responses. However, its ability to internalize oxidized LDL links it to atherosclerosis development. In cancer, SRA expression on tumor-associated macrophages (TAMs) may modulate tumor progression by influencing immune evasion and angiogenesis.
SRA antibodies are essential tools for studying these roles. They enable detection of SRA expression in tissues via techniques like immunohistochemistry and flow cytometry. Functional blocking antibodies are used to investigate SRA’s involvement in disease pathways, such as foam cell formation in atherosclerosis or immunosuppression in tumors. Additionally, SRA-targeting therapeutic antibodies are explored for modulating macrophage activity in inflammatory diseases and cancer immunotherapy. Research on SRA antibodies continues to clarify its complex roles in homeostasis, infection, and chronic diseases.
×
